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plots and multivariable competing risks regression models were used.
Results: The rates of testis-PL, renal-PL, bladder-PL and prostate-PL were 3.04%, 0.22%, 0.18%
and 0.01%, respectively. Patients with PGUL were older and more frequently Caucasian. Annual
rates significantly decreased for renal-PL (EAPC: 5.6%; p Z 0.004) and prostate-PL (EAPC:
3.6%; p Z 0.03). In multivariable logistic regression models, older ager independently pre-
dicted testis-PL (odds ratio [OR]: 16.4; p < 0.001) and renal-PL (OR: 3.5; p < 0.001), while fe-
male gender independently predicted bladder-PL (OR: 5.5; p < 0.001). In surgically treated
patients, cumulative incidence plots showed significantly higher 10-year cancer-specific mor-
tality (CSM) rates for testis-PL, renal-PL and prostate-PL versus their primary genitourinary tu-
mors. In multivariable competing risks regression models, only testis-PL (hazard ratio [HR]:
16.7; p < 0.001) and renal-PL (HR: 2.52; p < 0.001) independently predicted higher CSM rates.
Conclusion: PGUL rates are extremely low and on the decrease in kidney and prostate but sta-
ble in testis and bladder. Relative to primary genitourinary tumors, PGUL are associated with
worse CSM for testis-PL and renal-PL but not for bladder-PL and prostate-PL, even after adjust-
ment for other-cause mortality.
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Non-Hodgkin lymphomas (NHL) account for about 90% of all
lymphomas and they hold the seven highest incidence
rank. Men and elderly (>65 years) are predominantly
affected [1]. Approximately one-third of NHL arise from
sites other than lymph nodes, spleen or the bone marrow.
Primary extranodal lymphomas are defined as lymphomas
with no or only minor nodal involvement associated with a
clinically dominant extranodal component. They can
virtually originate in almost every organ [2].
The origin of primary extranodal lymphoma within the
genitourinary (GU, PGUL) tract is extremely rare. Of all
PGUL, testicular primary lymphoma (testis-PL) is the most
common type [3]. Conversely, those originate from the
kidney (renal-PL), the bladder (bladder-PL) and the pros-
tate (prostate-PL) cumulatively account for less than 0.5%
of all tumors affecting these three organs [4]. To date, only
one population-based study comprehensively focused on
the PGUL [5]. However, the study did not include testis-PL
and prostate-PL. One study examined testis-PL within a
population-based database [6], while only case reports are
available on prostate-PL [7].
Despite the availability of these studies, no direct
comparisons can be made between PGUL and primary GU
tumors. Moreover, all the previous studies considered both
localized and systemic disease, making difficult to assess
whether the extranodal involvement of the GU tract was
indeed primary or just secondary. However, at least occa-
sionally patients are surgically treated for a primary GU
tumor but eventually are found to harbor PGUL. From this
perspective, the lack of direct comparison represents an
unmet need. Therefore, we investigated rates, temporal
trends, demographics and survival outcomes of patients
with primary lymphoma of testis, kidney, bladder or pros-
tate relative their counterparts of primary GU, within the
Surveillance, Epidemiology, and End Results (SEER) data-
base from 1998 to 2015.et al., Primary lymphomas of th
jur.2019.11.0022. Methods
2.1. Data source and patient selection
Within the SEER database (1998e2015) [8], we focused on
patients aged 18 years or older, diagnosed with histologi-
cally confirmed malignancy of the genitourinary tract (In-
ternational Classification of Disease for Oncology [ICD-O]
site codes C62.1/C62.9, C.64.9, C67.0/C67.9 and C61.9, for
testis, kidney, bladder and prostate, respectively). We also
relied on the International Classification of Diseases ninth
edition codes to identify NHL [9], tumor of the testis (GCTT,
both seminomatous [SGCT] and non seminomatous
[NSGCT]), renal cell carcinoma (RCC), transitional cell
carcinoma of the bladder (TCC) and adenocarcinoma of the
prostate (PCa) cases [10]. Lymphomas were classified as
either low or high grade, based on World Health Organiza-
tion classification system [11]. All autopsy or death certif-
icate cases were excluded. In order to identify only PGUL
and therefore exclude secondary extranodal involvement,
we included only patients with localized disease (SEER
stage code). Consequently, all patients with either clinical
or pathological lymph-node involvement, as well as those
with metastatic disease, were excluded. Covariates
included age at diagnosis, gender, race, marital status, year
of diagnosis, residence area, socioeconomic status and
surgical treatment.2.2. Statistical analysis
Statistical analyses consisted of four analytical steps and
applied to all four groups. First, rates of PGUL were esti-
mated. Second, we examined the estimated annual per-
centage changes (EAPCs) of surgically-treated testis-PL,
renal-PL, bladder-PL and prostate-PL. The EAPC is calcu-
lated using a generalized linear model under the assump-
tion of linearity on the log scale, which is equivalent to ae genitourinary tract: A population-based study, Asian Journal of
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gistic regression models predicting the risk of diagnosis of
PGUL were fitted. Co-variates consisted of age, gender,
marital status, race and year of diagnosis. Fourth, cumu-
lative incidence plots depicted the cancer-specific mortal-
ity (CSM) and other-cause mortality (OCM) rates in testis-PL
vs. GCT, renal-PL vs. RCC, bladder-PL vs. TCC and prostate-
PL vs. PCa. Finally, multivariable competing risks regression
(CRR) models tested for CSM after adjustment for OCM in all
the four groups. Adjustment variables consisted of histo-
logical type, age, gender, race and year of diagnosis.
All statistical tests were two-sided with a level of sig-
nificance set at p < 0.05. Analyses were performed using
the R software environment for statistical computing and
graphics (version 3.4.1; http://www.r-project.org/).
3. Results
3.1. General characteristics and temporal trends
The rate of PGUL was 3.04% (470 out of 15 452 cases) for
testis-PL, 0.22% (249 out of 111 955) for renal-PL, 0.18%
(169 out of 93 780) for bladder-PL and 0.01% (83 out of
721 734) for prostate-PL. Table 1 summarizes the descrip-
tive characteristics of PGUL versus primary GU malig-
nancies according to sites of origin. Specifically, PGUL
patients exhibited significantly higher age at presentation
relative to GCTT, TCC and PCa patients (all p < 0.01).
Conversely, renal-PL patients exhibited significant lower
age at presentation relative to RCC patients (p < 0.001).
Additionally, the proportion of female was significantly
higher in bladder-PL patients, relative to TCC (64.5 vs.
23.5%, p < 0.001). Surgery was performed in 97.4% of testis-
PL (100% orchiectomy), in 38.6% of renal-PL (64.2% partial
and 36.8% radical nephrectomy), in 68.8% of bladder-PL
(98.3% transurethral resection and 1.7% radical cys-
tectomy) and in 55.4% of prostate-PL (97.9% transurethral
resection of the prostate and 2.1% radical prostatectomy).
The most common histological subtype of primary
extranodal lymphoma was diffuse large B-cell lymphoma
(DLBCL), followed by mantle cell lymphoma. Testis-PL,
renal-PL and bladder-PL were more often high grade
(86.4%, 48.2% and 43.2%, respectively). Conversely,
prostate-PL mostly showed low grade (45.8%) (Table 2).
No changes in EAPC were recoded for testis-PL (EAPC:
1.6%; p Z 0.06) and bladder-PL (EAPC: 3.6%; p Z 0.12).
Conversely, renal-PL and prostate-PL EAPC showed a sig-
nificant decrease over time (EAPC: 5.6%; p Z 0.004 and
EAPC: 3.6%; p Z 0.03, respectively).
3.2. Multivariable logistic regression models
predicting primary lymphoma
In multivariable logistic regression analyses (Table 3), in-
dependent predictors of higher testis-PL were older age
(odds ratio [OR]: 16.4; p < 0.001), African-American (OR:
3.1; p < 0.001) and other race (OR: 2.4; p < 0.001) relative
to Caucasian, while of lower rates were more contemporary
years (OR: 0.6; p < 0.001) relative to 1998e2003 period,Please cite this article as: Palumbo C et al., Primary lymphomas of th
Urology, https://doi.org/10.1016/j.ajur.2019.11.002and never married status (OR: 0.7; p Z 0.02), relative to
married status. Independent predictors of higher renal-PL
were older age (OR: 3.5; p < 0.001), other race (OR: 1.6;
pZ 0.03) relative to Caucasian and never married (OR: 1.7;
p Z 0.03) relative to married status. Independent pre-
dictors of higher bladder-PL were female (OR: 5.5;
p < 0.001) relative to male gender and other race (OR: 2.1;
p Z 0.005) relative to Caucasian, while of lower rates was
older age (OR: 0.6; p Z 0.04). Independent predictor of
higher prostate-PL rates was other race (OR: 2.6;
p Z 0.002) relative to Caucasian, while of lower rates was
age (OR: 0.4; p Z 0.04).
3.3. Survival analyses
At cumulative incidence plots (Fig. 1), 10-year CSM rates
were 28.3% vs. 0.9% for testis-PL vs. GCTT (p < 0.001),
15.3% vs. 8.3% for renal-PL vs. RCC (p Z 0.009), 23.2% vs.
23.0% for bladder-PL vs. TCC (p Z 0.37) and 35.6% vs. 2.5%
for prostate-PL vs. PCa (p < 0.001).
In separate multivariable competing risks regression
models predicting CSM after adjusting for OCM (Table 4),
testis-PL (hazard ratio [HR]: 17.3; p < 0.001) and prostate-
PL (HR 6.3; p < 0.001) independently predicted higher CSM
relative to their primary GU tumor. Conversely, renal-PL
and bladder-PL did not predict different CSM than their
primary GU tumors.4. Discussion
Approximately one-third of NHL arise from sites other than
lymph nodes, spleen or the bone marrow [2]. However, only
a small proportion of primary extranodal lymphoma affects
in the GU tract and may be incidentally diagnosed after
surgery for a suspected primary GU tumor. We analyzed the
SEER database to assess rates and variability over time as
well as survival outcomes of patients with localized PGUL,
relative to their primary GU tumor. Our analyses resulted in
several noteworthy findings.
First, we confirmed that localized PGUL are extremely
rare entities, involving 3.04%, 0.22%, 0.18% and 0.01% of all
localized neoplasms of testis, kidney, bladder and prostate,
respectively. In consequence a primary lymphoma within
kidney, bladder and prostate will be encountered in one out
of 10 000 patients. This rate is substantially higher in testis-
PL, nonetheless only one in 33 such patients will harbor
primary lymphoma among testis patients. This rates are
slightly inferior to those previously reported by Lontos
et al. [5] that considered all stages. Advanced age repre-
sented the most important indicator of PGUL in both testis-
PL and renal-PL, while female gender in bladder-PL.
Although a female predominance was also previously
recorded [13], due to rarity as well as absence of patho-
gnomonic features of renal-PL, bladder-PL and prostate-PL
the discrimination between primary lymphoma versus pri-
mary GU origin is virtually impossible. Conversely, more
advanced age in addition to characteristics that could not
be examined within the current study, such as appearance
on imaging and absence of tumor markers elevation, maye genitourinary tract: A population-based study, Asian Journal of
Table 1 Descriptive characteristics of primary lymphoma versus genitourinary malignancies according to sites of origin: Identified within the Surveillance, Epidemiology and
End Results database from 1998 to 2015.
Testicular tumors (n Z 15 452) Renal tumors (n Z 111 955) Bladder tumors (n Z 93 780) Prostate tumors (n Z 721 734)
PL (n Z 470;
3.0%)
GCTT























71 (58.5e78) 34 (28e42) <0.001 62 (52e70) 71 (63e78) <0.001 77 (67e84) 74 (65e81) 0.01 72 (63.5e78) 67 (60e74) 0.001
Surgery performed,
n (%)
458 (97.4) 14 929 (99.6) 96 (38.6) 102 380 (91.7) 116 (68.6) 89 847 (96.0) 46 (55.4) 233 565 (32.4)
Gender, n (%)
Male 470 (100) 14 972 (100) e 156 (62.7) 69 015 (61.8) <0.001 60 (35.5) 71 567 (76.5) <0.001 83 (100) 721 651 (100) e
Female e e e 93 (37.3) 42 691 (38.2) 109 (64.5) 22 044 (23.5) e e e
Race, n (%)
Caucasian 398 (84.7) 13 518 (90.2) <0.001 207 (83.1) 91 087 (81.5) 0.017 143 (84.6) 83 934 (89.7) 0.01 64 (77.1) 567 980 (78.7) 0.002
African-American 25 (5.3) 404 (2.7) 19 (7.6) 13 695 (12.3) 10 (5.9) 5316 (5.7) 6 (7.2) 103 123 (14.3)
Other 47 (10.0) 1060 (7.1) 23 (9.2) 6924 (6.2) 16 (9.5) 4361 (4.7) 13 (15.7) 50 631 (7.0)
Marital status, n (%) 140 (56.2)
Married 319 (67.9) 6997 (46.7) <0.001 38 (15.3) 69 650 (62.4) 0.025 77 (45.6) 55 009 (58.8) 0.001 54 (65.1) 478 102 (66.2) 0.04
Never married 53 (11.3) 6158 (41.1) 63 (25.3) 15 686 (14.0) 18 (10.7) 9019 (9.6) 12 (14.5) 64 574 (8.9)
Previously married 74 (15.7) 773 (5.2) 8 (3.2) 20 784 (18.6) 64 (37.9) 23 742 (25.4) 13 (15.7) 84 514 (11.7)
Unknown 24 (5.1) 1054 (7.0) 140 (56.2) 5586 (5.0) 10 (5.9) 5841 (6.2) 4 (4.8) 94 544 (13.1)






































































































Table 2 Descriptive characteristics of patients diagnosed with primary testicular lymphoma, primary renal lymphoma, pri-
mary bladder lymphoma or primary prostate lymphoma, identified within the Surveillance, Epidemiology and End Results
database from 1998 to 2015.
Variables Primary testicular
lymphoma (n Z 470)
Primary kidney
lymphoma (n Z 249)
Primary bladder
lymphoma (n Z 169)
Primary prostatic
lymphoma (n Z 83)
Histological subtype, n (%)
Mantle cell 3 (0.6) 0 (0) 2 (1.2) 5 (6.0)
Marginal zone 1 (0.2) 57 (22.9) 46 (27.2) 16 (19.3)
Follicular 0 (0) 24 (9.6) 7 (4.1) 6 (7.2)
Small lymphocytic 3 (0.6) 5 (2.0) 11 (6.5) 9 (10.8)
Lymphoplasmacytic 0 (0) 5 (2.0) 1 (0.6) 0 (0)
Mixed small large 2 (0.4) 1 (0.4) 0 (0) 2 (2.4)
DLBC 393 (83.6) 110 (44.2) 71 (42.0) 30 (36.1)
Burkitt 3 (0.6) 4 (1.6) 1 (0.6) 1 (1.2)
Lymphoblastic 4 (0.9) 3 (1.2) 1 (0.6) 0 (0)
Peripheral T cell 6 (1.3) 3 (1.2) 0 (0) 0 (0)
Not specified 44 (9.4) 37 (14.9) 29 (17.2) 14 (16.9)
Grade, n (%)
Low 20 (4.3) 92 (36.9) 67 (39.6) 38 (45.8)
High 406 (86.4) 120 (48.2) 73 (43.2) 31 (37.3)
Not specified 44 (9.4) 37 (14.9) 29 (17.2) 14 (16.9)
DLBC, diffuse large B cell.
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germ cell tumor.
Second, our analysis of PGUL according to histological
subtype showed variability according to the organ of origin
(testis, kidney, bladder or prostate). However, DLBCL was
the more frequent histological subtype, followed by mar-
ginal zone lymphomas and follicular lymphomas. These
distribution patterns are in agreement with more historic
reports from the SEER database where diagnosis wereTable 3 Multivariable logistic regression analyses predicting
(n Z 470), kidney (n Z 249), bladder (n Z 169) or prostate (n Z
Results database from 1998 to 2015.
Variables Testis Kidney
OR (95% CI) p-Value OR (95% CI)
Age, year 16.4 (9.3e30.8) <0.001 3.5 (2.3e5.4)
Gender
Male e e Ref
Female e e 0.8 (0.6e1.1)
Race
Caucasian Ref e Ref
AfricaneAmerican 3.1 (1.8e5.3) <0.001 0.7 (0.4e1.1)
Other 2.4 (1.6e3.6) <0.001 1.6 (1.1e2.4)
Marital status
Married Ref e Ref
Never married 0.7 (0.5e0.9) 0.02 1.7 (1.1e2.4)
Previously married 1.1 (0.8e1.6) 0.4 1.2 (0.9e1.7)
Unknown 0.7 (0.4e1.1) 0.1 0.7 (0.3e1.4)
Year of diagnosis
1998e2003 Ref e Ref
2004e2009 0.7 (0.5e0.9) 0.01 0.81 (0.58e1.1
2010e2015 0.6 (0.4e0.8) <0.001 0.78 (0.56e1.0
CI, confidence interval; OR, odds ratio; Ref, reference in multivariab
Please cite this article as: Palumbo C et al., Primary lymphomas of th
Urology, https://doi.org/10.1016/j.ajur.2019.11.002made from 1978 to 1995, where the rate of DLBCL was
about 40% [14,15].
Third, among surgically treated patients, annual trend
rates significantly decreased for both renal-PL and
prostate-PL (EAPC: 5.6%; p Z 0.004 and EAPC: 3.6%;
p Z 0.03, respectively), while no significant differences
were identified for both testis-PL and bladder-PL. Recently,
imaging criteria pertaining to ultrasound and computed-
tomography were proposed to distinguish betweenlocalized primary extranodal lymphoma of either testis
83), identified within the Surveillance, Epidemiology, and End
Bladder Prostate
p-Value OR (95% CI) p-Value OR (95% CI) p-Value
<0.001 0.6 (0.3e1.2) 0.04 0.4 (0.2e0.9) 0.04
e Ref e e e
0.3 5.5 (3.8e7.8) <0.001 e e
e Ref e Ref e
0.09 0.8 (0.4e1.4) 0.5 0.5 (0.2e1.1) 0.1
0.03 2.1 (1.2e3.4) 0.005 2.6 (1.4e4.6) 0.002
e Ref e Ref e
0.03 1.1 (0.6e1.7) 0.8 1.9 (0.9e3.4) 0.04
0.19 0.9 (0.6e1.3) 0.8 1.3 (0.9e2.3) 0.3
0.44 0.5 (0.2e0.9) 0.05 0.3 (0.1e0.8) 0.03
e Ref e Ref e
3) 0.22 1.1 (0.7e1.5) 0.8 1.1 (0.7e1.9) 0.6
9) 0.13 0.7 (0.5e1.1) 0.09 0.6 (0.3e1.2) 0.2
le analyses; e, not applicable.
e genitourinary tract: A population-based study, Asian Journal of
Figure 1 Cumulative incidence plots depicting cancer specific mortality (CSM) adjusted for other cause mortality (OCM) in (A)
primary testicular lymphoma vs. germ cell tumor, (B) renal cell carcinoma vs. primary renal lymphoma, (C) transitional cell car-
cinoma of the bladder vs. primary bladder lymphoma and (D) prostate adenocarcinoma vs. primary prostatic lymphoma.
Table 4 Multivariable competing risks regression models predicting cancer-specific mortality according to presence or
absence of lymphoma in testis, kidney, bladder and prostate cancer patients. All models are also adjusted for other-cause
mortality.
Testis Kidney Bladder Prostate
HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value
Histology
Primary tumor 1.0 (Ref.) e 1.0 (Ref.) e 1.0 (Ref.) e 1.0 (Ref.) e
Lymphoma 17.3 (10.7e28.1) <0.001 1.8 (0.9e3.4) 0.06 1.0 (0.7e1.6) 0.75 6.3 (3.1e12.5) <0.001
Age, year
<50 0.7 (0.4e1.2) 0.21 1.0 (Ref.) e 1.0 (Ref.) e 1.0 (Ref.) e
50e59 1.4 (0.8e2.2) 0.16 1.5 (1.4e1.7) <0.001 1.1 (0.9e1.2) 0.09 1.7 (1.3e2.3) <0.001
60e69 1.3 (0.7e2.5) 0.38 1.9 (1.7e2.0) <0.001 1.2 (1.1e1.4) <0.001 3.1 (2.4e4) <0.001
70e79 2.1 (1.1e4.1) 0.016 2.4 (2.2e2.6) <0.001 1.5 (1.4e1.7) <0.001 8.4 (6.6e10.9) <0.001
>80 1.8 (0.9e3.7) 0.09 3.4 (3.1e3.9) <0.001 2.6 (2.3e2.9) <0.001 30.8 (23.9e39.6) <0.001
Gender
Male e e 1.0 (Ref.) e 1.0 (Ref.) e e e
Female e e 0.8 (0.7e0.8) <0.001 1.2 (1.2e1.2) <0.001 e e
Race
Caucasian 1.0 (Ref.) e 1.0 (Ref.) e 1.0 (Ref.) e 1.0 (Ref.) e
AfricaneAmerican 1.8 (0.9e3.0) 0.08 1.1 (1.0e1.2) 0.006 1.4 (1.3e1.5) <0.001 1.6 (1.5e1.7) <0.001
Other 0.5 (0.3e1.1) 0.09 1.1 (0.9e1.1) 0.68 0.9 (0.8e0.9) 0.02 0.7 (0.6e0.8) <0.001
Year of diagnosis
1998e2003 1.0 (Ref.) e 1.0 (Ref.) e 1.0 (Ref.) e 1.0 (Ref.) e
2004e2009 0.7 (0.5e0.9) 0.02 0.7 (0.6e0.7) <0.001 1.0 (0.9e1.0) 0.8 0.7 (0.6e0.7) <0.001
2010e2015 0.6 (0.4e0.9) 0.01 0.5 (0.4e0.5) <0.001 0.9 (0.8e0.9) 0.001 0.6 (0.5e0.6) <0.001
HR, hazard ratio; Ref, reference; e, not applicable; 95% CI, 95% confidence interval.
6 C. Palumbo et al.
+ MODELprimary lymphomas and other tumor origins [16,17]. These
criteria may have resulted in recommendation for renal
biopsy in case of suspected renal-PL instead of upfront
surgery. Regarding testis-PL, orchiectomy may still bePlease cite this article as: Palumbo C et al., Primary lymphomas of th
Urology, https://doi.org/10.1016/j.ajur.2019.11.002required, even when testis-PL is clinically suspected with
the intent of eradicating a potential chemotherapy sanc-
tuary site due to the presence of the blood-testis
barrier [18]. Regarding bladder-PL and prostate-PL,e genitourinary tract: A population-based study, Asian Journal of
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+ MODELclinical presentation may include gross hematuria and/or
other urinary symptoms. In virtually all instance, tran-
surethral resection is necessary for diagnostic purpose.
Fourth, unlike any previous study, we tested CSM rates
after adjustment for OCM, since OCM may have an impor-
tant effect on CSM in all four examined GU organs with the
exception of testis. Ten-year CSM rates were significantly
higher for testis-PL, renal-PL and prostate-PL than for pri-
mary GU tumors, while no CSM differences were recorded
for bladder-PL vs. TCC. However, in multivariable
competing risks analyses, the survival disadvantage was
only confirmed for testis-PL (HR: 17.3; p < 0.001) and
prostate-PL (HR: 6.3; p < 0.001). These findings confirm the
higher aggressiveness of PGUL in testicular and prostatic
locations, even when diagnosed at localized stage. How-
ever, these differences may be also attributable to the
good prognosis of localized GCTT and PCa. To the best of
our knowledge, we are the first to perform a formal com-
parison between primary lymphoma and primary GU tumor
origin within testis, kidney, bladder and prostate. More-
over, we also adjusted for OCM, which is particularly
important in renal-PL, bladder-PL and prostate-PL since
they affect elderly patients who are at a significant higher
risk of OCM.
Despite its strengths, significant limitations of this study
need to be acknowledged. First, this study represents a
retrospective analysis with high potential for selection
biases. Second, the definition of primary extranodal lym-
phoma relied only on stage summary “localized” provided
by SEER database, with possible inclusion of secondary
extranodal involvement. Third, no standardized specimen
handling, as well as no central review regarding histological
subtype, was applied within the SEER database. Fourth, no
propensity score adjustment was performed while
comparing survival outcomes. To address this, the survival
analyses were performed only in surgically treated sub-
group. Moreover, data regarding earlier cancer control
endpoints, such as progression-free survival, are unavai-
lable in the SEER database and these represent additional
weaknesses. Finally, types and timing of administered
chemotherapy, as well as other systemic therapies, could
not be assessed in the SEER database. This limitation may
have led to selection biases and may limit the generaliz-
ability of our findings.Conclusion
PGUL rates are extremely low and on the decrease in kid-
ney and prostate but stable in testis and bladder. Relative
to primary genitourinary tumors, PGUL are associated with
worse CSM for testis-PL and renal-PL but not for bladder-PL
and prostate-PL, even after adjustment for other-cause
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